Atossa Genetics Company Insiders
| ATOS Stock | USD 1.19 0.01 0.83% |
Atossa Genetics employs about 12 people. The company is managed by 8 executives with a total tenure of roughly 28 years, averaging almost 3.0 years of service per executive, having 1.5 employees per reported executive. Breaking down Atossa Genetics' management performance can provide insight into the firm performance.
Atossa |
Atossa Genetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2035) % which means that it has lost $0.2035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.313) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.36 in 2024. At this time, Atossa Genetics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.2 M in 2024, whereas Intangible Assets are likely to drop slightly above 11.4 K in 2024.Common Stock Shares Outstanding is likely to gain to about 132.4 M in 2024, whereas Net Loss is likely to drop (25.5 M) in 2024.
Atossa Genetics Workforce Comparison
Atossa Genetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,136. Atossa Genetics maintains roughly 12.0 in number of employees contributing less than 1% to equities under Health Care industry.
Atossa Genetics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atossa Genetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Quay Steven C over two months ago Disposition of 2300000 shares by Quay Steven C of Atossa Genetics at 2.38 subject to Rule 16b-3 | ||
Steinhart Richard I over two months ago Acquisition by Steinhart Richard I of 50000 shares of Atossa Genetics at 0.93 subject to Rule 16b-3 | ||
Chen Shu-chih over two months ago Acquisition by Chen Shu-chih of 50000 shares of Atossa Genetics at 2.9 subject to Rule 16b-3 | ||
Remmel H. Lawrence over six months ago Acquisition by Remmel H. Lawrence of 45000 shares of Atossa Genetics at 1.7 subject to Rule 16b-3 | ||
Kyle Guse over six months ago Acquisition by Kyle Guse of 495333 shares of Atossa Genetics at 0.47 subject to Rule 16b-3 | ||
Gregory Weaver over a year ago Sale by Gregory Weaver of 50000 shares of Atossa Genetics | ||
Heather Rees over a year ago Atossa Genetics exotic insider transaction detected | ||
Gregory Weaver over a year ago Purchase by Gregory Weaver of 50000 shares of Atossa Genetics |
Atossa Genetics Notable Stakeholders
An Atossa Genetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atossa Genetics often face trade-offs trying to please all of them. Atossa Genetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atossa Genetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| RAC MSPH | VP of Regulatory Affairs and Quality | Profile | |
| Heather CPA | Senior Officer | Profile | |
| Heather Rees | VP Accounting | Profile | |
| FCAP MD | CEO Chairman | Profile | |
| Delly PHR | Vice Resources | Profile | |
| Eric Zanten | Vice Relations | Profile | |
| Richard MD | Interim Officer | Profile | |
| CPA Esq | Gen CFO | Profile |
About Atossa Genetics Management Performance
The success or failure of an entity such as Atossa Genetics often depends on how effective the management is. Atossa Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atossa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atossa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.33) | (0.35) |
Please note, the imprecision that can be found in Atossa Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atossa Genetics. Check Atossa Genetics' Beneish M Score to see the likelihood of Atossa Genetics' management manipulating its earnings.
Atossa Genetics Workforce Analysis
Traditionally, organizations such as Atossa Genetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atossa Genetics within its industry.Atossa Genetics Manpower Efficiency
Return on Atossa Genetics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 3.8M | |
| Working Capital Per Employee | 9.4M | |
| Working Capital Per Executive | 14.1M |
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.